Specialty Pharma Journal Specialty, Precision & Technology
FOSTER CITY, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 …
Tag Archives: gilead
December, 2018
-
5 December
Kite Announces Two-Year Data for Yescarta in Patients With Refractory Large B-Cell Lymphoma
SAN DIEGO–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of two years after a single infusion of Yescarta (median follow up of 27.1 months), 39 percent of patients …
November, 2018
-
9 November
Gilead Presents Data From Nonalcoholic Steatohepatitis Program for Advanced Fibrosis
SAN FRANCISCO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the company’s clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Data presented support the ongoing development of the company’s investigational compounds, evaluate the utility of noninvasive tests for the identification of patients with advanced fibrosis, …
-
1 November
Gilead and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics, Inc., a company focused on the discovery and development of novel cancer therapies, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under …
October, 2018
-
30 October
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy for Treatment of HIV-1 in Treatment-Naïve Adults
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the safety and efficacy of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF) for the treatment of HIV-1 infection in treatment-naïve adults. In the ongoing study, …
-
18 October
AELIX and Gilead Collaborate to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure
BARCELONA, Spain–(BUSINESS WIRE)–AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas …
-
3 October
Kite and HiFiBiO Collaborate to Develop Technology for Potential Discovery of Neoantigen-Reactive T Cell Receptors for the Treatment of Cancer
SANTA MONICA, Calif. & HONG KONG–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery …
September, 2018
-
25 September
Gilead Subsidiary to Launch Generics of Epclusa and Harvoni for the Treatment of Hepatitis C
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch …
-
12 September
Gilead and Precision BioSciences Collaborate to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
FOSTER CITY, Calif. & DURHAM, N.C.–(BUSINESS WIRE)–Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS. An estimated 257 million people are living with …
-
12 September
Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in Phase 3 Rheumatoid Arthritis Study
FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response/intolerance to biologic agents, achieved its …